American Uveitis Society Spring Meeting 2015
Rooms 708/710/712, Colorado Convention Center
2 May, 2015
Abstracts presented available here
Program
5.00 PM Social Hour (Room 703)
6.00 PM Plenary Session: Basis for and Uses of Biologic Drugs in Uveitis
Rachel Caspi, PhD
National Eye Institute, National Institutes of Health
“Mirroring the Clinical and Immunological Complexity of Autoimmune Uveitis in Animal Models”
Eric B. Suhler, MD, MPH
Oregon Health & Science University, VA Portland Health Care System
“Biologic Warfare on Uveitis: Perspectives from the Clinic”
7.00 PM Business Meeting
7.30 PM Free papers
7.30 PM Gary Holland, MD: Interaction between Killer Immunoglobulin-like Receptor (KIR) Gene-HLA Combinations and Parasite Serotypes among Hispanic Individuals at Risk for Ocular Toxoplasmosis
7.45 PM Douglas A. Jabs, MD, MBA: Long-term Outcomes of Cytomegalovirus Retinitis in the United States in the Era of Modern Antiretroviral Therapy
8.00 PM John A. Gonzales, MD: Quality of Life Outcomes from a Randomized Clinical Trial for Noninfectious Intermediate, Posterior, and Pan- Uveitis
8.15 PM Ali K. Tayyeba, MD: Management of End Stage Corneal Disease and Chronic Uveitic Hypotony by Combining the Boston Type 1 Keratoprosthesis with Pars Plana Vitrectomy and Silicone Oil Fill
8.30 PM Daniel L Feiler, MD: Treatment of Uveitic Cystoid Macular Edema with Topical Difluprednate.
8.45 PM Laura J. Kopplin, MD: Peginterferon alfa-2a (PEGASYS) in the Treatment of Inflammatory Cystoid Macular Edema
9.00 PM Blake A. Isernhagen, MD: Autoimmune Retinopathy: A Guide for Clinicians Based on Recommendations of an Expert Panel
9.15 PM Sarju S. Patel, MD: The Utility and Limitations of Wide-Field Autofluorescence in Inflammatory Choroiditis
9.30 PM Friederike Mackensen, MD: Is There a Correlation Between Multiple Sclerosis and Fuchs Uveitis
chaired by
Tammy M. Martin, PhD Casey Eye Institute, OHSU & Devers Eye Institute, LRI
Rooms 708/710/712, Colorado Convention Center
2 May, 2015
Program
5.00 PM Social Hour (Room 703)
6.00 PM Plenary Session: Basis for and Uses of Biologic Drugs in Uveitis
Rachel Caspi, PhD
National Eye Institute, National Institutes of Health
“Mirroring the Clinical and Immunological Complexity of Autoimmune Uveitis in Animal Models”
Eric B. Suhler, MD, MPH
Oregon Health & Science University, VA Portland Health Care System
“Biologic Warfare on Uveitis: Perspectives from the Clinic”
7.00 PM Business Meeting
7.30 PM Free papers
7.30 PM Gary Holland, MD: Interaction between Killer Immunoglobulin-like Receptor (KIR) Gene-HLA Combinations and Parasite Serotypes among Hispanic Individuals at Risk for Ocular Toxoplasmosis
7.45 PM Douglas A. Jabs, MD, MBA: Long-term Outcomes of Cytomegalovirus Retinitis in the United States in the Era of Modern Antiretroviral Therapy
8.00 PM John A. Gonzales, MD: Quality of Life Outcomes from a Randomized Clinical Trial for Noninfectious Intermediate, Posterior, and Pan- Uveitis
8.15 PM Ali K. Tayyeba, MD: Management of End Stage Corneal Disease and Chronic Uveitic Hypotony by Combining the Boston Type 1 Keratoprosthesis with Pars Plana Vitrectomy and Silicone Oil Fill
8.30 PM Daniel L Feiler, MD: Treatment of Uveitic Cystoid Macular Edema with Topical Difluprednate.
8.45 PM Laura J. Kopplin, MD: Peginterferon alfa-2a (PEGASYS) in the Treatment of Inflammatory Cystoid Macular Edema
9.00 PM Blake A. Isernhagen, MD: Autoimmune Retinopathy: A Guide for Clinicians Based on Recommendations of an Expert Panel
9.15 PM Sarju S. Patel, MD: The Utility and Limitations of Wide-Field Autofluorescence in Inflammatory Choroiditis
9.30 PM Friederike Mackensen, MD: Is There a Correlation Between Multiple Sclerosis and Fuchs Uveitis
